ArticleBioactive materials2021
HIF1α epigenetically repressed macrophages via CRISPR/Cas9-EZH2 system for enhanced cancer immunotherapy.
Article in Bioactive materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles.Materials today. Bio · 2026Review
- CAR-macrophages: a new chapter in cancer immunotherapy.Acta biochimica et biophysica Sinica · 2026Article
- EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives.Oncology research · 2026Review
- Molecular reprogramming in cutaneous melanoma: the central role of G9a and EZH2 methyltransferase inhibitors in tumor plasticity, immune evasion, and therapeutic resistance.Frontiers in pharmacology · 2026Review
- Specific macrophage RhoA targeting CRISPR-Cas9 for mitigating osteoclastogenesis-induced joint damage in inflammatory arthritis.Cell reports. Medicine · 2025Article
- Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy.Frontiers in immunology · 2025Review
- Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.Frontiers in immunology · 2025Review
- A dual-fluorescence assay for gene delivery vehicle screening in macrophages with an inflammation-inducible reporter construct.BMC methods · 2025Article
- Cardiac resident macrophages: Spatiotemporal distribution, development, physiological functions, and their translational potential on cardiac diseases.Acta pharmaceutica Sinica. B · 2024Review
- Review
- Epigenetic regulation of macrophage activation in chronic obstructive pulmonary disease.Frontiers in immunology · 2024Review
- The Potential Therapeutic Applications of CRISPR/Cas9 in Colorectal Cancer.Current medicinal chemistry · 2024Review
- The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.Biomarker research · 2023Review
- Nanodrugs Manipulating Endoplasmic Reticulum Stress for Highly Effective Antitumor Therapy.Frontiers in pharmacology · 2022Review
- Epigenetics Regulates Antitumor Immunity in Melanoma.Frontiers in immunology · 2022Review
- Molecular Characteristics of m6A Regulators and Tumor Microenvironment Infiltration in Soft Tissue Sarcoma: A Gene-Based Study.Frontiers in bioengineering and biotechnology · 2022Article
- Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages.Cells · 2021Review
- Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Frontiers in immunology · 2021Review
- Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune suppressive microenvironment in tumor emerges as the main obstacle for cancer immunotherapy. In this study, we identified that HIF1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.